REFERENCES
  1. Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Abdelali RB, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients. Am J Hematol. 28 juill 2020
  2. Legrand F, Renneville A, Macintyre E, Mastrilli S, Ackermann F, Cayuela JM, et al. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore). 2013;(5):e1-e9
  3. Qu SQ, Qin TJ, Xu ZF et al. Long term outcomes of Imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016; è (22): 33236.
  4. Helbig G, Soja A, Swiderska A, Hus M, Kyrcz-Krzemień S. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leuk Lymphoma. 2016; 57 (3): 708-710.
  5. Klion AD, Robyn J, Maric I et al. relapse following discontiniuation of Imatinib mesylate thérapye for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implication for optimal dosing. Boold 2007; 110 (10): 3552-3556.
  6. Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, et al. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020;4(3):440‑3.